Complement 3 Glomerulopathy (C3G) in 7 Major Markets (US, Germany,

On Nov 19, 2021

DUBLIN, November 19, 2021–(BUSINESS WIRE)–The “Complement 3 Glomerulopathy (C3G) – Market Insights, Epidemiology and Market Forecast – 2030” report has been added to ResearchAndMarkets.com’s offering.

This report delivers an in-depth understanding of the Complement 3 Glomerulopathy (C3G), historical and forecasted epidemiology as well as the C3G market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM C3G market size from 2018 to 2030. The report also covers current C3G treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Prevalent Population of Complement 3 Glomerulopathy (C3G), Type-specific Diagnosed Prevalent Population of Complement 3 Glomerulopathy (C3G) and Age-specific Diagnosed Prevalent Population of Complement 3 Glomerulopathy (C3G) in the 7MM market covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2018 to 2030.

Epidemiology: Key Findings

The total diagnosed prevalent population of Complement 3 Glomerulopathy (C3G) in the seven major markets was found to be 8,456 in 2020.
The diagnosed prevalent cases of Complement 3 Glomerulopathy (C3G), in the United States, were found to be 4,112 in 2020.
It was found that in the United States, the number of cases of DDD and C3GN was 1,398 and 2,714, respectively, in 2020.
Age-specific data for C3G suggests that in the United States the highest and the lowest number of cases of DDD were found in the age group of 18-50 with 860 cases and age-group 50 with 252 cases, respectively, in 2020, while the highest and the lowest number of cases of C3GN were found in the age group of 18-50 with 1,767 cases and age-group < 18 with 456 cases, respectively, in 2020.
In the EU5 countries, the diagnosed prevalence of Complement 3 Glomerulopathy (C3G) was found to be maximum in Germany with 848 cases, followed by the France with 708 cases in 2020. While, the least number of cases were found in Spain, with 511 cases in 2020.
In Japan, the diagnosed prevalence of Complement 3 Glomerulopathy (C3G) was found to be 942 in 2020.

Drug Chapters

The drug chapter segment of the Complement 3 Glomerulopathy (C3G) report encloses the detailed analysis of Complement 3 Glomerulopathy (C3G) marketed drugs and mid and late stage pipeline drugs. It also helps to understand the Complement 3 Glomerulopathy (C3G) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details of each included drug and the latest news and press releases.

Emerging Drugs

Danicopan (ACH-4471/ALXN2040): Alexion…